Equities

Zhejiang Starry Pharmaceutical Co Ltd

603520:SHH

Zhejiang Starry Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.94
  • Today's Change0.28 / 3.66%
  • Shares traded2.27m
  • 1 Year change-46.46%
  • Beta1.1150
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments453580684
Total Receivables, Net536759682
Total Inventory1,148739518
Prepaid expenses161216
Other current assets, total11283161
Total current assets2,2652,1722,062
Property, plant & equipment, net2,3642,2171,856
Goodwill, net405405520
Intangibles, net315327246
Long term investments129136160
Note receivable - long term------
Other long term assets------
Total assets5,5165,3024,895
LIABILITIES
Accounts payable373361322
Accrued expenses383645
Notes payable/short-term debt1,9901,8691,195
Current portion long-term debt/capital leases467418234
Other current liabilities, total647688
Total current liabilities2,9312,7601,886
Total long term debt734675747
Total debt3,1912,9622,176
Deferred income tax--1.38--
Minority interest6.305.9740
Other liabilities, total929448
Total liabilities3,7643,5372,720
SHAREHOLDERS EQUITY
Common stock343343245
Additional paid-in capital8118141,141
Retained earnings (accumulated deficit)605629823
Treasury stock - common0(25)(28)
Unrealized gain (loss)------
Other equity, total(6.1)3.74(5.51)
Total equity1,7531,7652,175
Total liabilities & shareholders' equity5,5165,3024,895
Total common shares outstanding343342342
Treasury shares - common primary issue00.921.03
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.